BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4
414 results:

  • 1. Abscisic acid signaling through LANCL2 and PPARγ induces activation of p38MAPK resulting in dormancy of prostate cancer metastatic cells.
    Parajuli KR; Jung Y; Taichman RS
    Oncol Rep; 2024 Mar; 51(3):. PubMed ID: 38624012
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Novel CDK19-Targeted Radiotracers: A Potential Design Strategy to Improve the Pharmacokinetics and Tumor Uptake.
    Dai D; Yu J; Gou W; Yang S; Li Y; Wang Z; Yang Z; Huang T; Li P; Zhu T; Hou W; Zhao Y; Xu W; Li Y
    J Med Chem; 2024 Apr; 67(8):6726-6737. PubMed ID: 38570733
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Curcumin Enhances the Anti-cancer Efficacy of CDK4/6 Inhibitors in prostate cancer.
    Zhao H; Ding R; Han J
    Arch Esp Urol; 2024 Jan; 77(1):57-66. PubMed ID: 38374014
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Female Bladder Dysfunction Following Boari Bladder Flap Ureteral Reconstruction.
    Hardesty JK; Burns RT; Soyster ME; Jansen NE; Mellon M
    Urology; 2024 Apr; 186():31-35. PubMed ID: 38369201
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice.
    Papadopoulou E; Rigas G; Fountzilas E; Boutis A; Giassas S; Mitsimponas N; Daliani D; Ziogas DC; Liontos M; Ramfidis V; Christophilakis C; Matthaios D; Floros T; Florou-Chatzigiannidou C; Agiannitopoulos K; Meintani A; Tsantikidi A; Katseli A; Potska K; Tsaousis G; Metaxa-Mariatou V; Nasioulas G
    JCO Precis Oncol; 2024 Jan; 8():e2300332. PubMed ID: 38271656
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. First-in-human study of PSMA-targeting agent, [
    Zhao R; Ke M; Lv J; Liu S; Liu Y; Zhang J; Xu L; Gu D; Li M; Cai C; Liu Y; Zeng G; Alexoff D; Ploessl K; Zhu L; Kung HF; Wang X
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1753-1762. PubMed ID: 38212531
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Resistance to 2-Hydroxy-Flutamide in prostate cancer Cells Is Associated with the Downregulation of Phosphatidylcholine Biosynthesis and Epigenetic Modifications.
    Mora-Rodríguez JM; Sánchez BG; Sebastián-Martín A; Díaz-Yuste A; Sánchez-Chapado M; Palacín AM; Sánchez-Rodríguez C; Bort A; Díaz-Laviada I
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958610
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
    Rautajoki KJ; Jaatinen S; Hartewig A; Tiihonen AM; Annala M; Salonen I; Valkonen M; Simola V; Vuorinen EM; Kivinen A; Rauhala MJ; Nurminen R; Maass KK; Lahtela SL; Jukkola A; Yli-Harja O; Helén P; Pajtler KW; Ruusuvuori P; Haapasalo J; Zhang W; Haapasalo H; Nykter M
    Acta Neuropathol Commun; 2023 Nov; 11(1):176. PubMed ID: 37932833
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Aridanin and oleanane-3- O-β-D-glucoside-2'-acetamide obtained from Tetrapleura tetraptera (Schumach. & Thonn) Taub. (Fabaceae) induces potent apoptotic activity in human prostate cancer cells.
    Kamdem MHK; Zingue S; Grein T; Maxeiner S; Rutz J; Mmutlane EM; Njamen D; Blaheta RA; Ndinteh DT
    J Ethnopharmacol; 2024 Jan; 319(Pt 3):117298. PubMed ID: 37866463
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. p16 expression in urothelial carcinoma: Experience from a tertiary care center in coastal South India.
    Sachdeva S; Suresh PK; Basavaiah SH; Sahu KK; Sreeram S; Kini H; Kini JR; Pinto AC
    J Cancer Res Ther; 2023; 19(5):1330-1334. PubMed ID: 37787303
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Characterization of Human Papilloma Virus in prostate cancer Patients Undergoing Radical prostatectomy-A Prospective Study of 140 Patients.
    Nellessen T; Ebner B; Pyrgidis N; Ledderose S; Kretschmer A; Marcon J; Teupser D; Mayr D; Faihs V; Stief CG; French LE; Herlemann A; Reinholz M
    Viruses; 2023 May; 15(6):. PubMed ID: 37376564
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. PET imaging of new target CDK19 in prostate cancer.
    Dai D; Yu J; Huang T; Li Y; Wang Z; Yang S; Li S; Li Y; Gou W; Li D; Hou W; Fan S; Li Y; Zhao Y
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3452-3464. PubMed ID: 37278941
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. A prospective head-to-head comparison of [
    Wang G; Li L; Zhu M; Zang J; Wang J; Wang R; Yan W; Zhu L; Kung HF; Zhu Z
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3126-3136. PubMed ID: 37233785
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent prostate cancer.
    Zamboglou C; Peeken JC; Janbain A; Katsahian S; Strouthos I; Ferentinos K; Farolfi A; Koerber SA; Debus J; Vogel ME; Combs SE; Vrachimis A; Morganti AG; Spohn SKB; Shelan M; Aebersold DM; Grosu AL; Ceci F; Henkenberens C; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Bartenstein P; Hruby G; Scharl S; Wiegel T; Emmett L; Arnoux A; Schmidt-Hegemann NS
    JAMA Netw Open; 2023 May; 6(5):e2314748. PubMed ID: 37219907
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Utility of GATA-3 and associated immunohistochemical markers in the differential diagnosis of poorly differentiated urothelial carcinoma.
    Naik M; Rao BV; Challa S; Fonseca D; Sudha SM; Giridhar A; Sharma R; Raju KVVN; Rao TS
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147963
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Epigenetics regulation of prostate cancer: Biomarker and therapeutic potential.
    Ragavi R; Muthukumaran P; Nandagopal S; Ahirwar DK; Tomo S; Misra S; Guerriero G; Shukla KK
    Urol Oncol; 2023 Aug; 41(8):340-353. PubMed ID: 37032230
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Senescent Tumor Cells Are Frequently Present at the Invasion Front: Implications for Improving Disease Control in Patients with Locally Advanced prostate cancer.
    Schwarz S; Nientiedt C; Prigge ES; Kaczorowski A; Geisler C; Lucena Porcel C; von Knebel Doeberitz M; Hohenfellner M; Duensing S
    Pathobiology; 2023; 90(5):312-321. PubMed ID: 37004506
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns.
    Sørensen SG; Shrikhande A; Poulsgaard GA; Christensen MH; Bertl J; Laursen BE; Hoffmann ER; Pedersen JS
    Elife; 2023 Mar; 12():. PubMed ID: 36883553
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. The small GTPase arf3 controls invasion modality and metastasis by regulating N-cadherin levels.
    Sandilands E; Freckmann EC; Cumming EM; Román-Fernández A; McGarry L; Anand J; Galbraith L; Mason S; Patel R; Nixon C; Cartwright J; Leung HY; Blyth K; Bryant DM
    J Cell Biol; 2023 Apr; 222(4):. PubMed ID: 36880595
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Head-to-Head Comparison of 68 Ga-p16-093 and 68 Ga-PSMA-617 PET/CT in Patients With Primary prostate cancer : A Pilot Study.
    Wang G; Li L; Zang J; Hong H; Zhu L; Kung HF; Zhu Z
    Clin Nucl Med; 2023 Apr; 48(4):289-295. PubMed ID: 36727866
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 21.